Is Vimta Labs overvalued or undervalued?
As of June 30, 2025, Vimta Labs is considered overvalued with a PE ratio of 32.65 and other high valuation metrics, despite a strong 1-year return of 87.63%, indicating caution for potential investors.
As of 30 June 2025, the valuation grade for Vimta Labs has moved from fair to expensive, indicating a shift in perception regarding its market value. The company appears to be overvalued based on its current metrics, with a PE ratio of 32.65, a Price to Book Value of 5.82, and an EV to EBITDA of 17.45. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.When compared to peers, Vimta Labs' PE ratio is significantly lower than that of Poly Medicure, which stands at 66.66, and Blue Jet Health at 49.79, both categorized as very expensive. Additionally, the PEG ratio of 0.65 indicates that Vimta Labs may be undervalued in terms of growth relative to its price, yet the overall valuation suggests it is overvalued at this time. Despite recent stock performance showing a strong 1-year return of 87.63% compared to the Sensex's 5.79%, the current valuation metrics warrant caution for potential investors.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
